Underdog Pharmaceuticals is a
pharmaceutical startup founded in
2019. The company's slogan emphasizes its focus on pioneering solutions that address the root causes of age-related diseases through targeted intervention and innovative molecular design.
Underdog Pharmaceuticals is dedicated to developing straightforward solutions targeting harmful forms of cholesterol through the use of intelligently designed molecules. This pioneering approach aims to offer the first genuinely effective treatments for conditions such as atherosclerosis, hypercholesterolemia, heart failure, and macular degeneration. The company's products are based on innovative derivatives of a well-known, safe compound and are informed by a fresh perspective on cardiovascular disease emerging from a
SENS Research Foundation initiative.
The latest development for Underdog Pharmaceuticals is a significant milestone, as the company secured a
$10.00M Seed Round investment on
23 September 2021 from
Kizoo Technology Capital. This injection of capital is expected to drive the company's research and development efforts towards bringing their innovative treatments to market.
